P
Panaxia Labs Israel Ltd
TASE:PNAX
Panaxia Labs Israel Ltd
TASE:PNAX
Price:
5 192
ILS
-1.05%
Market Cap:
₪7.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
P
|
Panaxia Labs Israel Ltd
TASE:PNAX
|
IL |
|
P
|
Pacifico Renewables Yield AG
XETRA:PRY
|
DE |
|
S
|
Salee Industry PCL
SET:SALEE
|
TH |
|
E
|
Etteplan Oyj
OMXH:ETTE
|
FI |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of PNAX.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PNAX
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
PNAX Competitors Multiples
Panaxia Labs Israel Ltd Competitors
Panaxia Labs Israel Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
P
|
Panaxia Labs Israel Ltd
TASE:PNAX
|
7.9m ILS | 0.3 | -0.3 | -1.8 | -1.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879.7B USD | 13.5 | 42.6 | 28.8 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.1B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.2 | 11.4 | 12.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232B GBP | 5.4 | 30.9 | 17.1 | 24 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.2B USD | 4.5 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.9B CHF | 5.2 | 20.9 | 12.9 | 16.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.6 | 7.8 | 9.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.1B USD | 2.4 | 16.5 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
